These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effect of sodium glycyrrhetinate on neonatal rat myocardial cells.
    Author: Zhu XW, Meng FM.
    Journal: Zhongguo Yao Li Xue Bao; 1996 Jul; 17(4):331-3. PubMed ID: 9812716.
    Abstract:
    AIM: To investigate the effect of sodium glycyrrhetinate (SG) on neonatal rat myocardial cells. METHODS: The neonatal rat myocardial cells were cultured in vitro. Radioimmunoassay and fluorimetry were used to determine cAMP and [Ca2+], respectively. RESULTS: The beating rate of myocardial cells was depressed by SG 0.4 mmol.L-1 at 5, 10, and 15 min, from 73 +/- 9 min-1 to 62 +/- 5, 59 +/- 7, and 56 +/- 6 min-1, respectively. SG 0.1 and 0.2 mmol.L-1 showed above similar results at 15 min and 10, 15 min, respectively. When the myocardial cells were incubated with SG 0.2 and 0.4 mmol.L-1 at 37 degrees C for 10 and 15 min, the concentration of cAMP and- [Ca2+] were reduced. cAMP contents in SG 0.2 mmol.L-1 treated group at 10 and 15 min were lower than control group (1.09 +/- 0.18 vs 1.65 +/- 0.48 pmol per vial, P < 0.05; 1.12 +/- 0.35 vs 1.72 +/- 0.49 pmol per vial, P < 0.01), and so was [Ca2+] (30 +/- 4 nmol.L-1 vs 41 +/- 6 nmol.L-1, P < 0.05 and 28 +/- 6 nmol.L-1 vs 38 +/- 7 nmol.L-1, P < 0.01). SG 0.1 and 0.2 nmol.L-1 increased the pO2 change rate (87% +/- 5%, 75% +/- 4% vs 54% +/- 3%, P < 0.01) in suspension fluid of myocardial cells, but SG 0.4 mmol.L-1 decreased it (31% +/- 2% vs 54% +/- 3%, P < 0.01). CONCLUSION: SG protects myocardium or treats ischemic cardiac disease.
    [Abstract] [Full Text] [Related] [New Search]